<DOC>
	<DOCNO>NCT00399321</DOCNO>
	<brief_summary>The main purpose study see level Bone Mineral Density post-menopausal woman breast cancer , see level Bone Mineral Density change woman 's treatment surgery . This trial study change Bone Mineral Density marker bone activity post-menopausal woman receive treatment early stage breast cancer .</brief_summary>
	<brief_title>A Pilot Study Bone Mineral Density Postmenopausal Women After Treatment Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<criteria>Documented diagnosis breast cancer Last menstrual period occur 5 year ago Nonmetastatic breast cancer tumor diagnosis Tis , TlT4 , N03 , M0 DCIS allow , LCIS ( ) Any metabolic bone disease postmenopausal osteoporosis osteopenia Use systemic gonadal hormonal medication supplement within past 24 month Prior use tamoxifen raloxifene permit medication discontinue 24 month prior diagnosis breast cancer . No adjuvant antiestrogen , antineoplastic , therapy permit study . Chronic use systemic steroid disease process breast cancer chemotherapy premedication antiemetic History rheumatoid arthritis , ankylose spondylitis , hyperparathyroidism , renal osteodystrophy , moderate severe inflammatory autoimmune disease newly diagnose thyroid condition require titration medication . Lobular carcinoma situ Stage IV breast cancer patient concurrently active second malignancy adequately treat nonmelanoma skin cancer situ cervical cancer . participation clinical trial measure BMD study parameter Patients condition expect distort BMD read make DEXA result unreliable Patients concurrent medical psychiatric condition would keep understand comply clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Post menopause woman receive adjuvant care</keyword>
</DOC>